Crossmark

Antibiotic therapy and outcome from immune-checkpoint inhibitors

Crossref DOI link: https://doi.org/10.1186/s40425-019-0775-x

Published Online: 2019-11-06

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Pinato, David J. https://orcid.org/0000-0002-3529-0103
Gramenitskaya, Daria

Altmann, Daniel M.

Boyton, Rosemary J.

Mullish, Benjamin H.

Marchesi, Julian R.

Bower, Mark
License Information

Text and Data Mining valid from 2019-11-06
More Information

Article History

Received: 12 July 2019

Accepted: 9 October 2019

First Online: 6 November 2019

Ethics approval and consent to participate

: n/a.

: n/a.

: Dr. Pinato reports receiving grant funding in support of clinical trials from Merck Sharpe and Dohme and Bristol Myers Squibb and having received speaker/consultancy fees from ViiV Healthcare, Bayer and MiNa therapeutics outside the submitted work. There are no other conflicts of interest to report.